| Autor: |
Timmer-Bonte JN; Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. j.timmer@onco.umcn.nl, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC |
| Jazyk: |
angličtina |
| Zdroj: |
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2008 May; Vol. 60 (2), pp. 222-30. Date of Electronic Publication: 2007 Nov 19. |
| DOI: |
10.1016/j.lungcan.2007.10.001 |
| Abstrakt: |
In advanced non-small cell lung cancer (NSCLC) the clinical benefit of a platinum-based doublet is only modest, therefore, attenuated dosed three-drug combinations are investigated. We hypothesized that with adequate support a full dosed chemotherapy triplet is feasible. The study was designed as a dose finding study of paclitaxel in chemotherapy-naive patients. Paclitaxel was given as a 3-h infusion on day 1, followed by fixed doses of teniposide (or etoposide) 100mg/m(2) days 1, 3, 5 and cisplatin 80 mg/m(2) day 1 every 3 weeks. As myelotoxicity was expected to be the dose-limiting toxicity, prophylactic G-CSF and antibiotic support was evaluated. Indeed, paclitaxel 120 mg/m(2) resulted in dose-limiting neutropenia, despite G-CSF support. Teniposide/etoposide day 1, 3, 5 was less myelotoxic compared to day 1, 2, 3. G-CSF support allowed paclitaxel dose-escalation to 250 mg/m(2). The addition of prophylactic antibiotics enabled dose-escalation to 275 mg/m(2) without reaching MTD. In conclusion, G-CSF and antibiotics prophylaxis enables the delivery of a full dosed chemotherapy triplet in previously untreated NSCLC patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect